You are here

Our People

With approximately 130 personnel employed at CRT, we’re an experienced, dedicated and highly motivated team. The roles are split between drug discovery and commercialisation for a comprehensive approach to getting breakthrough therapeutics to patients. We have employees across sites in London and Cambridge, Boston (US) and throughout CRUK research institutes and centres.

OUR BOARD Open

Peter Chambré, Chairman. Mr. Peter A. Chambre has been Chairman of CRT since October 2011. He has been Independent Non-Executive Director of BTG Plc., since September 2006 and Chairman of Xellia Pharmaceuticals AS, OneMed AB and 7TM Pharma A/S. He is also a non-executive director of Spectris plc, the precision instrumentation and controls company. Peter was Chief Executive Officer of Cambridge Antibody Technology Group plc from 2002 until its acquisition by AstraZeneca plc in 2006. Previously he was Chief Operating Officer of Celera Genomics Group and Chief Executive of Bespak plc.


 

Dr Andy Richards CBE. Dr Andy Richards CBE is a biotechnology entrepreneur and investor. His current business activity focuses on growing successful biotechnology and healthcare technology companies. He is currently Chairman of Ixicio plc, Congenica Limited, Novacta Biosystems Limited, Abcodia Limited and Cambridge Temperature Concepts Limited, as well as a director of Arecor Limited, Ieso Health Limited (formerly PsychologyOnline.co.uk Limited) and Babraham Bioscience Technologies Limited. Andy is also a director of Cambridge University Health Trust and an adviser to Vectura Group plc. He was a founder of Chiroscience, one of Europe’s most successful biotech companies, and an executive director through to the merger with Celltech in 1999. Since that time he has been founding, investing in and directing new UK healthcare and life science companies. Andy joined the board of CRT is August 2003. He is a graduate of Cambridge University with a PhD in Chemistry.
 


Iain Foulkes, PhD. Having been on the CRT board since 2013, Iain was appointed CEO of CRT at the beginning of 2017. He is responsible for ensuring research is developed and commercialised, often in partnership with biotech and pharmaceutical companies, to ensure the outputs of research reach patients as rapidly and effectively as possible. Iain is also Executive Director, Research & Innovation, CRUK, and is responsible for helping to shape the long-term direction of the Charity and to ensure we have effective strategies to meet our ambitious goals. Iain began his career as a research scientist, completing his PhD at the Cancer Research UK Beatson Institute, before becoming a science writer and medical journalist and joining Cancer Research UK.


Sir Harpal S Kumar. Harpal is Chief Executive of Cancer Research UK, appointed in 2007 following three years as Chief Operating Officer and five years as Chief Executive of Cancer Research Technology. Harpal was Chair of the Taskforce and author of “Achieving World-Class Cancer Outcomes: A Strategy for England 2015-2020”, published in summer 2015. He is a Trustee of The Francis Crick Institute in London. He also chairs the National Cancer Advisory Group is a member of the MedCity Advisory Board. He is a Director of UICC. He was knighted in the 2016 New Years Honours list.


 

Phil L'Huillier. Phil has 20+ years experience in the biotech/pharma industry, in R&D, IP management, licensing and partnering and strategic development. As CRT's Executive Director, Business Management, Phil has successfully executed CRT’s innovative drug discovery alliance strategy, overseen 30+ industrial partnerships and ventured-backed new companies annually, and developed a team of 28 BD staff to be “one of best in Europe” commercialisation operations servicing some 450 scientists/clinicians across 30 organisations. Phil has served Non-Executive Director roles with Hybrid Biosystems Ltd, PsiOxus Therapeutics Ltd, Blink Therapeutics Ltd and was Chairman of Senectus Ltd. Prior to joining CRT, Phil was Global Head of Licensing and Business Development at BioFocus Discovery Ltd (now Galapagos), then an AIM-listed hybrid drug discovery company. Prior to BioFocus, Phil was CSO and more recently CEO of ProBio Inc, a US specialty IP commercialisation company involved in international licensing and partnering in the Life Sciences sectors, prior to its sale to Pharming Group NV. He has also been a consultant to industry advising clients on R&D and commercialisation strategies, and has worked across several continents, including North America, Europe, New Zealand and Australia. Phil holds an MBA, and a PhD in cellular and molecular biology.


Deborah Harland. Deborah has extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during her more than 25 year tenure in the pharmaceutical industry. She joined SR One, the corporate venture capital arm of GlaxoSmithKline, in 2005 to establish the firm’s European investment office. Deborah is currently a member of the Board of Directors of Asceneuron, Mission Therapeutics, Bicycle Therapeutics, f-star, Atopix Therapeutics and VH Squared. She was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO,  SIX Swiss Exchange, 2007), Pharmakodex Limited (sold to Orexo) and Syntaxin Limited (sold to Ipsen) and an observer on the Boards of Ablynx (IPO, Euronext  Brussels 2007) and 7TM Pharma. Deborah received her BSc. (Hons.) in Pharmacology from the University of Bath, her PhD in Pharmacology from the University of London, and her MBA from Henley Management College.

CSO and CRT-DL Open

Clive Stanway, Chief Scientific Officer Clive is responsible for the external scientific profile of CRT as well as the strategic analysis and development of the CRT project portfolio. Before moving to this role, he led the drug discovery and biotherapeutic discovery activity of CRT. Prior to the formation of CRT in 2002, he was Director of Project Development for Imperial Cancer Research Technology, a role which focused on the identification and development of projects with therapeutic potential. From his time in the private sector, he has 5 years' experience in drug discovery gained whilst working for Xenova and Prolifix where he held the positions of Head of Assay Development and Head of Biology, respectively. In the academic part of Clive's career he held several postdoctoral positions at Oxford University. He has a PhD from Imperial College and a BSc from Nottingham University.


Hamish Ryder, Director of Drug Discovery Hamish has directed drug discovery at CRT-DL since 2008. He has led the successful transition of our translational strategy to a themed multi-project alliance model where industry partners are involved from the earliest stages of target selection and triage. Prior to joining CRT-DL he held positions in pharmaceutical and biotech companies for over 20 years, the most recent of which was as Director of Research at Almirall, Spain’s largest pharmaceutical company. Hamish has worked in a number of therapeutic areas, including autoimmune, inflammatory, respiratory, GI, CNS and cancer. He has led organisations that have discovered multiple candidate drugs for regulatory development, thus far resulting in approved therapies for chronic obstructive pulmonary disease (Bretaris and Duaklir). Hamish obtained his first degree in Natural Sciences and a PhD in organic chemistry from the University of Cambridge.


Tim Hammonds, Deputy Director of Drug Discovery Tim has been in his current role at CRT-DL since April 2014. He leads multiple aspects of translational drug discovery and has strategic responsibility for the design, planning, negotiation and management of multi-site academia-industry alliances. During his 16 years at CRT, Tim has been central to establishing our small molecule drug discovery capabilities. Tim joined CRT-DL after 5 years postdoctoral enzymology research at the University of Leicester. He has a degree in Pharmacy and a PhD in pharmaceutical chemistry and microbiology from the University of Nottingham.


> Read more about CRT-DL

BUSINESS DEVELOPMENT Open

Dr Phil L'Huillier, Executive Director, Business Management Phil has 20+ years experience in the biotech/pharma industry, in R&D, IP management, licensing and partnering and strategic development. At CRT, Phil has successfully executed CRT’s innovative drug discovery alliance strategy, overseen 30+ industrial partnerships and ventured-backed new companies annually, and developed a team of 28 BD staff to be “one of best in Europe” commercialisation operations servicing some 450 scientists/clinicians across 30 organisations.  Phil has served Non-Executive Director roles with Hybrid Biosystems Ltd, PsiOxus Therapeutics Ltd, Blink Therapeutics Ltd and was Chairman of Senectus Ltd. Prior to joining CRT, Phil was Global Head of Licensing and Business Development at BioFocus Discovery Ltd (now Galapagos), then an AIM-listed hybrid drug discovery company. Prior to BioFocus, Phil was CSO and more recently CEO of ProBio Inc, a US specialty IP commercialisation company involved in international licensing and partnering in the Life Sciences sectors, prior to its sale to Pharming Group NV. He has also been a consultant to industry advising clients on R&D and commercialisation strategies, and has worked across several continents, including North America, Europe, New Zealand and Australia. Phil holds an MBA, and a PhD in cellular and molecular biology.


Dr Phil Masterson, Associate Director, Business Management Phil has been working as Associate Director of Business Management at CRT since June 2011. Phil has a BSc in Cell Biology from the University of Essex, and a PhD in Virology from the University of Cambridge. After a post-doc position at the National Institute for Medical Research (NIMR) in London, Phil spent a number of years managing R&D programmes in the biotech industry. He moved into technology transfer in 2003 when he joined the Business Development team at CRT. Since that time he has built up extensive experience of managing and commercialising healthcare technologies from academic origins.


Dr Laura Fletcher, Associate Director, Business Management Laura obtained her first degree in Biochemistry from the University at Bristol and, after a one year sabbatical at the University of Pennsylvania, returned to Bristol to take up her PhD in insulin signalling and resistance. Her focus during this time was on cell biology and time-lapse confocal microspcopy. Shortly after completing her PhD in 2001, Laura was the co-founder of a small molecule drug discovery company called ProXara, where she spent the following five years developing fluorescent cellular screens focussed on identifying inhibitors of protein localisation events for various cancer targets. During this time she also managed the associated patent portfolio and was involved in seed fund raising and business plan development. Laura joined CRT’s Business Management team in summer 2006, and in June 2011 was promoted to Associate Director. 


 Dr Angus Lauder, Associate Director, Business Management. After obtaining a BSc in Molecular Biology from the University of Edinburgh, Angus moved to London to complete a PhD at the Institute of Cancer Research working on signal transduction and gene expression of the oncogene c-Myb. He then undertook post-doctoral research studies at the MRC Laboratory of Molecular Biology in Cambridge working on models of leukaemia and the roles of cytokines in controlling leukaemia development. Angus has worked at CRT for twelve years during which time he has worked on a wide range of therapeutic projects, research technologies and biomarker opportunities. During this time he has gained in-depth experience of a broad set of translational and commercialisation models including licensing, industry-academia alliances and formation of a number of spin-out companies. Angus currently manages a team of five business managers and provide strategic input and advice to the team to facilitate translation of technologies from a range of university partners using many different commercialisation routes and models.


Dr Phil Elstob, Head of Commercial Portfolio. Phil leads a team with responsibility for CRT’s portfolio of over 100 licences and ~30 equity holdings. Phil joined CRT following the completion of a PhD in developmental biology at the MRC’s National Institute for Medical Research (Mill Hill, London) and has since gained over 15 years’ experience in the development, IP management and commercialisation of cancer therapeutics. In 2006 Phil moved back to his native northeast to set up a strategic partnership with Newcastle University, and he currently works part-time for both CRT and the University. More recently Phil spent two and a half years as part-time Chief Executive Officer of Demuris Limited, a University spin out company focused on antibiotic drug discovery. Phil is also a member of the PraxisUnico Training Committee, responsible for the design and delivery of training courses for knowledge exchange and commercialisation professionals.


> Read more about our services

CRT INC. Open

  Andrea Schievella, Head of Business Development at CRT Inc. Andrea has been focused on partnering early stage life sciences technologies for over 15 years. Since 2008 she has been at CRT Inc, building relationships between CRT/CRUK and the biotech/pharma industry and venture firms throughout the US. Prior to CRT, Andrea was at MIT's Technology Licensing Office, where she regularly engaged with both established and startup companies to license technology from MIT, the Whitehead Institute and Lincoln Laboratory. Previous to that, Andrea was one of the first ten employees at Variagenics, a personalized medicine startup out of MIT. Initially hired as a scientist, after three years Andrea transitioned into business development, where she focused on alliance development in the US and Europe for a further three years until the company was acquired. Andrea received her undergraduate degree in Biology at MIT and her PhD from Harvard, followed by a three-year postdoctoral fellowship with Genetics Institute's Small Molecule Drug Discovery group.  

 


> View our projects

CLINICAL DEVELOPMENT PARTNERSHIPS Open

Dr Victoria John, Head of Clinical Partnerships (CRUK) Vicky joined Cancer Research UK in March 2008. In her role as Head of Clinical Partnerships, Vicky is responsible for sourcing new projects for the CRUK Centre for Drug Development and negotiating clinical trial agreements for CDP projects. Prior to joining Cancer Research UK, Vicky worked at Cancer Research Technology for 9 years including 4 years as a Senior Business Manager and 2 years as Head of Licensing for the CDP initiative. During her time at Cancer Research Technology Vicky concluded a number of major collaboration and licence agreements, and spent 2 years as a non-executive Board Director for Hybrid Systems. Vicky holds a first class BSc (Hons) in Molecular Biology from the University of Manchester and, following a period of working in assay development at Glaxo-Wellcome, completed a PhD in Oncology from the Paterson Institute for Cancer Research.


> Read more about CDP

RESEARCH TOOLS Open

Dr Melanie Hardman, Head of Ximbio Melanie has 17 years experience in commercial life science business development within the scientific software and life science reagents sectors. Prior to joining CRT Melanie worked for Oxford Molecular, Accelrys and LION Bioscience primarily in customer facing sales and pre-sales roles with global pharma, biotech and academic customers. Melanie has been with CRT for over 10 years and heads up the research reagents business unit, which in this time has doubled in size (2000+ research reagents) and revenues and launched an online portal, Ximbio (www.ximbio.com). The business has a dedicated team and is responsible for commercialising non patented materials generated from CRUK funded research and making these valuable tools widely and easily available through sales and licensing to the life science reagents industry. Melanie has a PhD in microbiology.


> Read more about research tools

  • Peter Chambré, Chairman. Mr. Peter A. Chambre has been Chairman of CRT since October 2011. He has been Independent Non-Executive Director of BTG Plc., since September 2006 and Chairman of Xellia Pharmaceuticals AS, OneMed AB and 7TM Pharma A/S. He is also a non-executive director of Spectris plc, the precision instrumentation and controls company. Peter was Chief Executive Officer of Cambridge Antibody Technology Group plc from 2002 until its acquisition by AstraZeneca plc in 2006. Previously he was Chief Operating Officer of Celera Genomics Group and Chief Executive of Bespak plc.


     

    Dr Andy Richards CBE. Dr Andy Richards CBE is a biotechnology entrepreneur and investor. His current business activity focuses on growing successful biotechnology and healthcare technology companies. He is currently Chairman of Ixicio plc, Congenica Limited, Novacta Biosystems Limited, Abcodia Limited and Cambridge Temperature Concepts Limited, as well as a director of Arecor Limited, Ieso Health Limited (formerly PsychologyOnline.co.uk Limited) and Babraham Bioscience Technologies Limited. Andy is also a director of Cambridge University Health Trust and an adviser to Vectura Group plc. He was a founder of Chiroscience, one of Europe’s most successful biotech companies, and an executive director through to the merger with Celltech in 1999. Since that time he has been founding, investing in and directing new UK healthcare and life science companies. Andy joined the board of CRT is August 2003. He is a graduate of Cambridge University with a PhD in Chemistry.
     


    Iain Foulkes, PhD. Having been on the CRT board since 2013, Iain was appointed CEO of CRT at the beginning of 2017. He is responsible for ensuring research is developed and commercialised, often in partnership with biotech and pharmaceutical companies, to ensure the outputs of research reach patients as rapidly and effectively as possible. Iain is also Executive Director, Research & Innovation, CRUK, and is responsible for helping to shape the long-term direction of the Charity and to ensure we have effective strategies to meet our ambitious goals. Iain began his career as a research scientist, completing his PhD at the Cancer Research UK Beatson Institute, before becoming a science writer and medical journalist and joining Cancer Research UK.


    Sir Harpal S Kumar. Harpal is Chief Executive of Cancer Research UK, appointed in 2007 following three years as Chief Operating Officer and five years as Chief Executive of Cancer Research Technology. Harpal was Chair of the Taskforce and author of “Achieving World-Class Cancer Outcomes: A Strategy for England 2015-2020”, published in summer 2015. He is a Trustee of The Francis Crick Institute in London. He also chairs the National Cancer Advisory Group is a member of the MedCity Advisory Board. He is a Director of UICC. He was knighted in the 2016 New Years Honours list.


     

    Phil L'Huillier. Phil has 20+ years experience in the biotech/pharma industry, in R&D, IP management, licensing and partnering and strategic development. As CRT's Executive Director, Business Management, Phil has successfully executed CRT’s innovative drug discovery alliance strategy, overseen 30+ industrial partnerships and ventured-backed new companies annually, and developed a team of 28 BD staff to be “one of best in Europe” commercialisation operations servicing some 450 scientists/clinicians across 30 organisations. Phil has served Non-Executive Director roles with Hybrid Biosystems Ltd, PsiOxus Therapeutics Ltd, Blink Therapeutics Ltd and was Chairman of Senectus Ltd. Prior to joining CRT, Phil was Global Head of Licensing and Business Development at BioFocus Discovery Ltd (now Galapagos), then an AIM-listed hybrid drug discovery company. Prior to BioFocus, Phil was CSO and more recently CEO of ProBio Inc, a US specialty IP commercialisation company involved in international licensing and partnering in the Life Sciences sectors, prior to its sale to Pharming Group NV. He has also been a consultant to industry advising clients on R&D and commercialisation strategies, and has worked across several continents, including North America, Europe, New Zealand and Australia. Phil holds an MBA, and a PhD in cellular and molecular biology.


    Deborah Harland. Deborah has extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during her more than 25 year tenure in the pharmaceutical industry. She joined SR One, the corporate venture capital arm of GlaxoSmithKline, in 2005 to establish the firm’s European investment office. Deborah is currently a member of the Board of Directors of Asceneuron, Mission Therapeutics, Bicycle Therapeutics, f-star, Atopix Therapeutics and VH Squared. She was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO,  SIX Swiss Exchange, 2007), Pharmakodex Limited (sold to Orexo) and Syntaxin Limited (sold to Ipsen) and an observer on the Boards of Ablynx (IPO, Euronext  Brussels 2007) and 7TM Pharma. Deborah received her BSc. (Hons.) in Pharmacology from the University of Bath, her PhD in Pharmacology from the University of London, and her MBA from Henley Management College.

  • Clive Stanway, Chief Scientific Officer Clive is responsible for the external scientific profile of CRT as well as the strategic analysis and development of the CRT project portfolio. Before moving to this role, he led the drug discovery and biotherapeutic discovery activity of CRT. Prior to the formation of CRT in 2002, he was Director of Project Development for Imperial Cancer Research Technology, a role which focused on the identification and development of projects with therapeutic potential. From his time in the private sector, he has 5 years' experience in drug discovery gained whilst working for Xenova and Prolifix where he held the positions of Head of Assay Development and Head of Biology, respectively. In the academic part of Clive's career he held several postdoctoral positions at Oxford University. He has a PhD from Imperial College and a BSc from Nottingham University.


    Hamish Ryder, Director of Drug Discovery Hamish has directed drug discovery at CRT-DL since 2008. He has led the successful transition of our translational strategy to a themed multi-project alliance model where industry partners are involved from the earliest stages of target selection and triage. Prior to joining CRT-DL he held positions in pharmaceutical and biotech companies for over 20 years, the most recent of which was as Director of Research at Almirall, Spain’s largest pharmaceutical company. Hamish has worked in a number of therapeutic areas, including autoimmune, inflammatory, respiratory, GI, CNS and cancer. He has led organisations that have discovered multiple candidate drugs for regulatory development, thus far resulting in approved therapies for chronic obstructive pulmonary disease (Bretaris and Duaklir). Hamish obtained his first degree in Natural Sciences and a PhD in organic chemistry from the University of Cambridge.


    Tim Hammonds, Deputy Director of Drug Discovery Tim has been in his current role at CRT-DL since April 2014. He leads multiple aspects of translational drug discovery and has strategic responsibility for the design, planning, negotiation and management of multi-site academia-industry alliances. During his 16 years at CRT, Tim has been central to establishing our small molecule drug discovery capabilities. Tim joined CRT-DL after 5 years postdoctoral enzymology research at the University of Leicester. He has a degree in Pharmacy and a PhD in pharmaceutical chemistry and microbiology from the University of Nottingham.


    > Read more about CRT-DL

  • Dr Phil L'Huillier, Executive Director, Business Management Phil has 20+ years experience in the biotech/pharma industry, in R&D, IP management, licensing and partnering and strategic development. At CRT, Phil has successfully executed CRT’s innovative drug discovery alliance strategy, overseen 30+ industrial partnerships and ventured-backed new companies annually, and developed a team of 28 BD staff to be “one of best in Europe” commercialisation operations servicing some 450 scientists/clinicians across 30 organisations.  Phil has served Non-Executive Director roles with Hybrid Biosystems Ltd, PsiOxus Therapeutics Ltd, Blink Therapeutics Ltd and was Chairman of Senectus Ltd. Prior to joining CRT, Phil was Global Head of Licensing and Business Development at BioFocus Discovery Ltd (now Galapagos), then an AIM-listed hybrid drug discovery company. Prior to BioFocus, Phil was CSO and more recently CEO of ProBio Inc, a US specialty IP commercialisation company involved in international licensing and partnering in the Life Sciences sectors, prior to its sale to Pharming Group NV. He has also been a consultant to industry advising clients on R&D and commercialisation strategies, and has worked across several continents, including North America, Europe, New Zealand and Australia. Phil holds an MBA, and a PhD in cellular and molecular biology.


    Dr Phil Masterson, Associate Director, Business Management Phil has been working as Associate Director of Business Management at CRT since June 2011. Phil has a BSc in Cell Biology from the University of Essex, and a PhD in Virology from the University of Cambridge. After a post-doc position at the National Institute for Medical Research (NIMR) in London, Phil spent a number of years managing R&D programmes in the biotech industry. He moved into technology transfer in 2003 when he joined the Business Development team at CRT. Since that time he has built up extensive experience of managing and commercialising healthcare technologies from academic origins.


    Dr Laura Fletcher, Associate Director, Business Management Laura obtained her first degree in Biochemistry from the University at Bristol and, after a one year sabbatical at the University of Pennsylvania, returned to Bristol to take up her PhD in insulin signalling and resistance. Her focus during this time was on cell biology and time-lapse confocal microspcopy. Shortly after completing her PhD in 2001, Laura was the co-founder of a small molecule drug discovery company called ProXara, where she spent the following five years developing fluorescent cellular screens focussed on identifying inhibitors of protein localisation events for various cancer targets. During this time she also managed the associated patent portfolio and was involved in seed fund raising and business plan development. Laura joined CRT’s Business Management team in summer 2006, and in June 2011 was promoted to Associate Director. 


     Dr Angus Lauder, Associate Director, Business Management. After obtaining a BSc in Molecular Biology from the University of Edinburgh, Angus moved to London to complete a PhD at the Institute of Cancer Research working on signal transduction and gene expression of the oncogene c-Myb. He then undertook post-doctoral research studies at the MRC Laboratory of Molecular Biology in Cambridge working on models of leukaemia and the roles of cytokines in controlling leukaemia development. Angus has worked at CRT for twelve years during which time he has worked on a wide range of therapeutic projects, research technologies and biomarker opportunities. During this time he has gained in-depth experience of a broad set of translational and commercialisation models including licensing, industry-academia alliances and formation of a number of spin-out companies. Angus currently manages a team of five business managers and provide strategic input and advice to the team to facilitate translation of technologies from a range of university partners using many different commercialisation routes and models.


    Dr Phil Elstob, Head of Commercial Portfolio. Phil leads a team with responsibility for CRT’s portfolio of over 100 licences and ~30 equity holdings. Phil joined CRT following the completion of a PhD in developmental biology at the MRC’s National Institute for Medical Research (Mill Hill, London) and has since gained over 15 years’ experience in the development, IP management and commercialisation of cancer therapeutics. In 2006 Phil moved back to his native northeast to set up a strategic partnership with Newcastle University, and he currently works part-time for both CRT and the University. More recently Phil spent two and a half years as part-time Chief Executive Officer of Demuris Limited, a University spin out company focused on antibiotic drug discovery. Phil is also a member of the PraxisUnico Training Committee, responsible for the design and delivery of training courses for knowledge exchange and commercialisation professionals.


    > Read more about our services

  •   Andrea Schievella, Head of Business Development at CRT Inc. Andrea has been focused on partnering early stage life sciences technologies for over 15 years. Since 2008 she has been at CRT Inc, building relationships between CRT/CRUK and the biotech/pharma industry and venture firms throughout the US. Prior to CRT, Andrea was at MIT's Technology Licensing Office, where she regularly engaged with both established and startup companies to license technology from MIT, the Whitehead Institute and Lincoln Laboratory. Previous to that, Andrea was one of the first ten employees at Variagenics, a personalized medicine startup out of MIT. Initially hired as a scientist, after three years Andrea transitioned into business development, where she focused on alliance development in the US and Europe for a further three years until the company was acquired. Andrea received her undergraduate degree in Biology at MIT and her PhD from Harvard, followed by a three-year postdoctoral fellowship with Genetics Institute's Small Molecule Drug Discovery group.  

     


    > View our projects

  • Dr Victoria John, Head of Clinical Partnerships (CRUK) Vicky joined Cancer Research UK in March 2008. In her role as Head of Clinical Partnerships, Vicky is responsible for sourcing new projects for the CRUK Centre for Drug Development and negotiating clinical trial agreements for CDP projects. Prior to joining Cancer Research UK, Vicky worked at Cancer Research Technology for 9 years including 4 years as a Senior Business Manager and 2 years as Head of Licensing for the CDP initiative. During her time at Cancer Research Technology Vicky concluded a number of major collaboration and licence agreements, and spent 2 years as a non-executive Board Director for Hybrid Systems. Vicky holds a first class BSc (Hons) in Molecular Biology from the University of Manchester and, following a period of working in assay development at Glaxo-Wellcome, completed a PhD in Oncology from the Paterson Institute for Cancer Research.


    > Read more about CDP

  • Dr Melanie Hardman, Head of Ximbio Melanie has 17 years experience in commercial life science business development within the scientific software and life science reagents sectors. Prior to joining CRT Melanie worked for Oxford Molecular, Accelrys and LION Bioscience primarily in customer facing sales and pre-sales roles with global pharma, biotech and academic customers. Melanie has been with CRT for over 10 years and heads up the research reagents business unit, which in this time has doubled in size (2000+ research reagents) and revenues and launched an online portal, Ximbio (www.ximbio.com). The business has a dedicated team and is responsible for commercialising non patented materials generated from CRUK funded research and making these valuable tools widely and easily available through sales and licensing to the life science reagents industry. Melanie has a PhD in microbiology.


    > Read more about research tools